I also wonder if the ongoing lawsuit regarding ownership of the DED tests will be resolved with a bit of AXIM equity as well. That has been lingering too long with limited action.
The Auer Precision partnership has given me confidence that Manufacturing will no longer be the bottle neck in the process.
Additionally Auer Precision spells out on their website the capability of helping clients bring product ideas to market a lot faster with their laboratories and technologies.
My opinion is Auer Precision was a great choice by AXIM.
In addition to manufacturing becomming stabilized we now have Verséa Ophthalmics providing updates on LinkedIn when a doctor's office has successfully completed compliance training and received their initial shipment of product.
In other words we have proof of cashflow. After 5 months of silence we finally have proof of AXIM products inside eye doctor's offices.
Market Data 
Markets 
AI
